Application value of portal vein flow velocity after different interventions on rebleeding in patients with hepatitis B cirrhosis complicated with esophageal and gastric variceal bleeding
10.3760/cma.j.cn311365-20210127-00029
- VernacularTitle:不同干预后的门静脉流速对乙型肝炎肝硬化合并食管胃底静脉曲张破裂出血患者再出血的应用价值
- Author:
Wanrong QI
1
;
Xiaorong MAO
;
Junfeng LI
Author Information
1. 兰州大学第一临床医学院 730000
- Keywords:
Hepatitis B;
Liver cirrhosis;
Esophagogastric varix rebleeding;
Portal vein flow velocity
- From:
Chinese Journal of Infectious Diseases
2021;39(10):598-603
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the predictors of rebleeding three months after treatment of esophageal and gastric variceal bleeding (EGVB) in patients with hepatitis B cirrhosis and the effects of different treatments on rebleeding.Methods:From January 2018 to January 2020, the hepatitis B cirrhosis patients with first onset of EGVB in the First Hospital of Lanzhou University were enrolled and followed up for three months. The development of rebleeding, information about portal vein flow velocity and model for end-stage liver disease (MELD) scores after treatment of first bleeding were collected. The statistical analysis was conducted by chi-square test and binary logistic regression analysis. The efficacy for predictors of rebleeding was evaluated by using area under the receiver operating characteristic curve.Results:Among the 33 patients with the first EGVB, the rebleeding rate during three months follow-up was 42% (14 cases), including one patient (1/8) who underwent transjugular intrahepatic portosystemic shunt, 10 patients (10/19) were treated with therapeutic endoscopy, and three patients (3/6) were treated with vasoactive drugs. No statistically significant difference in rebleeding rates was found among the three treatment groups ( χ2=3.853, P=0.175). Portal vein flow velocity after treatment for the first onset of EGVB (odds ratio ( OR)=0.21, 95% confidence interval ( CI) 0.05 to 0.93, P=0.039) and MELD score ( OR=1.53, 95% CI 1.02 to 2.30, P=0.040) were independent predictors for the occurrence of rebleeding events during three months. When the portal vein flow velocity after treatment for the first bleeding was 19 cm/s, the area under the receiver operating characteristic curve for prediction of the occurrence of rebleeding during three months was 0.86, with the sensitivity of 92% and the specificity of 61%. Conclusion:Among the patients with hepatitis B cirrhosis and the first onset of EGVB, different treatments may have little relationship with three-month rebleeding, while portal vein flow velocity ≤19 cm/s is the main predictor for rebleeding within three months.
